Although limited cases and the absence of specific clinical trials for thyroid IMT preclude definitive conclusions, the molecular similarities of IMT suggest that ALK-positive thyroid IMT patients may benefit from ALK inhibitors, particularly in cases where surgery is not feasible or recurrence occurs. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.